Galapagos NV: Galapagos refocuses pipeline and rightsizes operations
Filgotinib launch in Europe on track
Initiated
unaudited
the
. These last months, we completed a review of our portfolio and development plans with the goal to select a more risk-balanced pipeline. We decided to retain our focus on novel targets to address unmet medical needs in inflammation, fibrosis, and kidney diseases. We also remain fully committed to the launch of Jyseleca in Europe. Moving forward with confidence, we decided to:
Refocus our clinical pipeline by critically examining its risk profile and breadth;
Cut significant cost in the organization to support this re-sized pipeline development;
.
“These last months, we completed a review of our portfolio and development plans with the goal to select a more risk-balanced pipeline. We decided to retain our focus on novel targets to address unmet medical needs in inflammation, fibrosis, and kidney diseases. We also remain fully committed to the launch of Jyseleca in Europe. Moving forward with confidence, we decided to:
Refocus our clinical pipeline by critically examining its risk profile and breadth;
Cut significant cost in the organization to support this re-sized pipeline development;
Task our business development team to identify and execute on a transformative opportunity.
We believe that our strong cash position, expert teams, and solid scientific foundation position us well for future growth,” said Onno van de Stolpe, CEO of Galapagos.
Search jobs 06-May-2021 Asia-Pacific Lung Cancer Therapeutics Market Incredible Possibilities, Growth with Industry Study, Detailed Analysis and Forecast to 2027 The reliable
“XYZ” report presents the best market and business solutions to Industry in this rapidly revolutionizing marketplace to thrive in the market. This market research report is a vigilant investigation of the current scenario of the market and future estimations which spans several market dynamics. The market definition gives the scope of a particular product with respect to the driving factors and restraints in the market.
This industry document forecasts the size of the market with information on key vendor revenues, development of the industry by upstream and downstream, industry progress, key companies, along market segment type and market application. Key data and information used while preparing this market report have been collected from consistent
First-Quarter 2021 Net Sales of $342.4 Million; First-Quarter 2021 GAAP Net Loss of $123.4 Million; Adjusted EBITDA of $45.8 Million First-Quarter 2021 Orphan Segment Net Sales Increased
Total product and royalty revenues of $605 million in Q1 2021 (+6% vs Q1 2020) Jakafi® (ruxolitinib) revenues of $466 million in Q1 2021 (+1% vs Q1 2020); reaffirming full year guidance of $2.125-$2.20 billionPemazyre® (pemigatinib) now also approved in Europe and Japan, becoming the first internally discovered pro.